Coherus BioSciences and Mark Cuban’s Cost Plus Drug Company will shake up the Humira and Humira-referenced biosimilar space with the launch of Yusimry at a 85% discount.
Coherus BioSciences And Mark Cuban’s Drug Company Aim To Disrupt Humira-Referenced Biosimilar Space With Launch Of Yusimry At A 85% Discount
